Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Basilea Pharmaceutica's book value per share for the quarter that ended in Dec. 2025 was CHF10.41.
During the past 12 months, Basilea Pharmaceutica's average Book Value Per Share Growth Rate was 55.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Basilea Pharmaceutica was 55.40% per year. The lowest was -50.00% per year. And the median was -6.90% per year.
During the past 13 years, the highest P/B Ratio of Basilea Pharmaceutica was 56.51. The lowest was 4.78. And the median was 6.99.
Good Sign:
Basilea Pharmaceutica Ltd stock PB Ratio (=5.26) is close to 10-year low of 4.78.
Basilea Pharmaceutica (XSWX:BSLN) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Basilea Pharmaceutica Book Value per Share Related Terms
Basilea Pharmaceutica Book Value per Share Historical Data
* Premium members only.
The historical data trend for Basilea Pharmaceutica's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:BSLN vs VRTX, REGN, ALNY: Book Value per Share Comparison
For the Biotechnology subindustry, Basilea Pharmaceutica's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Basilea Pharmaceutica PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Basilea Pharmaceutica's PB Ratio distribution charts can be found below:
* The bar in red indicates where Basilea Pharmaceutica's PB Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Book Value per Share of CHF10.41 mean?
Basilea Pharmaceutica (XSWX:BSLN) has a Book Value per Share of CHF10.41 as of Dec. 2025. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Basilea Pharmaceutica and its competitors.
Is Basilea Pharmaceutica's Book Value per Share too high?
Basilea Pharmaceutica's current Book Value per Share is CHF10.41. Overall, Basilea Pharmaceutica has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Basilea Pharmaceutica's Book Value per Share compare to VRTX and REGN?
Basilea Pharmaceutica's Book Value per Share of CHF10.41 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Book Value per Share for a Biotechnology company?
A good Book Value per Share depends on the Biotechnology industry context. However, Book Value per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Book Value per Share mean?
A high Book Value per Share can signal that a stock is expensive relative to its fundamentals. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Basilea Pharmaceutica and its competitors. Basilea Pharmaceutica's current Book Value per Share is CHF10.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Basilea Pharmaceutica stock overvalued right now?
Based on GuruFocus' analysis, Basilea Pharmaceutica (XSWX:BSLN) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF57.77, compared to a current price of CHF51.80 — trading 10.3% below its estimated fair value. The current Book Value per Share is CHF10.41. Basilea Pharmaceutica's overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Book Value per Share calculated?
Book Value per Share is calculated from a company's financial statements. For Basilea Pharmaceutica (XSWX:BSLN), the current Book Value per Share is CHF10.41 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Basilea Pharmaceutica (XSWX:BSLN) Overvalued in 2026?
Based on GuruFocus' analysis, Basilea Pharmaceutica stock appears to be undervalued.
The current stock price of CHF51.80 is trading 10.3% below its estimated GF Value™ of CHF57.77.
GuruFocus considers Basilea Pharmaceutica to be Modestly Undervalued.
Key valuation signals for XSWX:BSLN:
Book Value per Share: CHF10.41
GF Value™: CHF57.77 vs. price of CHF51.80 (10.3% below fair value)
No single metric tells the full story. See the XSWX:BSLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.
58GF Score
Get the complete analysis for XSWX:BSLN
Book Value per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BSLN has been successfully added to your 
